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Background: Infection by Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae, either alone or together,
causes serious respiratory diseases in pigs.
Results: To develop an efficient multi-disease subunit vaccine against these pathogens, we produced a chimeric
protein called Ap97, which comprises a deletion derivative of the N-terminal region of the A. pleuropneumoniae ApxIII
toxin (ApxN) and the R1 and R2 repeats of M. hyopneumoniae P97 adhesin (P97C), using an E. coli expression system.
The levels of both IgG1 and IgG2a isotypes specific for ApxN and P97C in the sera of Ap97-immunized mice increased,
and Ap97 induced the secretion of IL-4 and IFN-γ by mouse splenocytes. Antisera from mice and pigs immunized with
Ap97 readily reacted with both native ApxIII and P97 proteins. In addition, immunization with the Ap97 vaccine
effectively protected pigs against challenge with both pathogens.
Conclusions: These findings suggest that Ap97 confers immunogenicity, and is an effective vaccine that protects pigs
against infection by M. hyopneumoniae and A. pleuropneumoniae.
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Actinobacillus pleuropneumoniae is the etiological agent
responsible for porcine pleuropneumonia, a contagious
and potentially fatal respiratory disease in pigs [1-3].
Based on differences in the capsular polysaccharides, 15
serotypes of A. pleuropneumoniae have been identified
to date, which show significant variation with respect to
virulence and geographical distribution. Most of those
serotypes secrete one or more A. pleuropneumoniae toxin
(Apx), identified as ApxI, ApxII, ApxIII, and ApxIV. Apx
toxins are major virulence factors of A. pleuropneumoniae
and are highly immunogenic. It is well accepted that ApxI
and ApxIII are highly toxic for porcine neutrophils
and pulmonary alveolar macrophages, and ApxII only
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unless otherwise stated.A. pleuropneumoniae vaccines include inactivated whole-
cell bacterins as well as the more promising subunit vac-
cines and live attenuated vaccines [4]. Most commercially
available vaccines against A. pleuropneumoniae infection
comprise inactivated whole-cell bacterins derived from
various serotypes of A. pleuropneumoniae [5]. However,
bacterins confer only partial protection against homolo-
gous serotypes and do not usually protect against challenge
with heterologous serotypes [6,7]. In addition, a large
number of mutants were generated and used to produce
live attenuated vaccines [8-10]. However, live attenuated
vaccines present a number of bio-safety concerns.
Many studies show that subunit vaccines elicit an
effective immune response and provide protection against
A. pleuropneumoniae infection. Apx proteins have been
studied as potential candidates for the development of
vaccines against porcine pleuropneumoniae because they
are highly immunogenic. Many commercially available A.
pleuropneumoniae subunit vaccines contain recombinant. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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taining components of Apx toxin have been produced
for vaccine development. Some epitopes of ApxIA were
inserted into the B subunit of E. coli heat-labile enterotoxin,
and the immunogenicity of the chimeric proteins was
analyzed in mice [12]. Recently, ApxIIA fused with the
cholera toxin B subunit was expressed in corn as a subunit
vaccine candidate [13].
Mycoplasma hyopneumoniae is the etiological agent
responsible for porcine enzootic pneumonia, a chronic
non-fatal disease that affects pigs of all ages [14]. Pigs
with primary mycoplasmal infection are predisposed to
potentially fatal secondary infections by the porcine
reproductive and respiratory syndrome virus, Pasteurella
multocida, and A. pleuropneumoniae [15-17].
Commonly used vaccines against M. hyopneumoniae
comprise inactivated whole-cell bacterins. Although
bacterin-based vaccines often reduce the infection level in
a herd, protection against clinical pneumonia is usually not
complete [18,19]. In an experimental transmission study, a
bacterin vaccine reduced the transmission of M. hyopneu-
moniae only to a limited extent [20]. Moreover, preparation
of bacterin vaccines is not economically advantageous,
because in vitro culture of M. hyopneumoniae is time-
consuming and requires a rich medium [21].
P97 adhesin is highly conserved among different strains
of M. hyopneumoniae [22,23]. P97 is essential for the
adherence of M. hyopneumoniae to ciliated respiratory
epithelial cells. The C-terminus of P97 contains two repeat
regions, designated R1 and R2, which play key roles in
adherence [24,25]. Following the discovery of a functional
role for the C-terminus of P97, much effort has been made
to develop vaccines based on this region, in particular the
R1 and R2 repeats.
A recombinant chimera comprising the R1 region of
P97 and E. coli enterotoxin B induced increased humoral
and cellular immune responses in mice when compared
with the recombinant R1 region alone [26]. Another
chimera comprising the R1 region and a domain of Pseudo-
monas exotoxin A stimulated a higher IgG response to
the R1 region than a commercial M. hyopneumoniae
vaccine [27].
Live bacteria harboring vectors encoding either R1, or
R1 and R2, have also been evaluated for their potential
as vaccines against M. hyopneumoniae infection. Mice
that orally ingested Salmonella typhimurium harboring
eukaryotic or prokaryotic expression vector encoding the
R1 region showed R1-specific Th1 responses [28]. Intrana-
sal and oral immunization of Erysipelothrix rhusiopathiae
strains expressing the C-terminal portion of P97, including
the R1 and R2 regions, to pigs reduced the severity of pneu-
monic lung lesions caused by M. hyopneumoniae infection
[29,30]. Adenovirus expressing the C-terminal portion
of P97, containing the R1 and R2 regions, also inducedprotective P97-specific humoral and cellular immune
responses in pigs [31].
There is a high demand for multi-disease vaccines in
the swine industry due to the high labor costs incurred
by vaccination and because of injection-induced stress in
pigs. This is particularly true for preventing M. hyopneumo-
niae infection and/or secondary infection induced by A.
pleuropneumoniae [16]. Therefore, the aim of the present
study was to produce a chimeric fusion protein comprising
the N-terminal portion of ApxIII and the C-terminal por-
tion of P97 using an E. coli expression system, and to
analyze its immunogenicity and protective effects against
infection by M. hyopneumoniae and A. pleuropneumoniae.
Methods
Chemicals
All chemicals were of reagent grade or higher and were
obtained from Sigma-Aldrich (St. Louis, MO), unless
otherwise specified.
Microbial culture
A. pleuropneumoniae strain 1536 (serotype 2) and M.
hyopneumoniae strain J were purchased from the American
Type Culture Collection (ATCC, Manassas, VA). A
wild-type strain of M. hyopneumoniae was isolated from
the lung tissues of pigs suffering from porcine enzootic
pneumonia.
The A. pleuropneumoniae strain was cultured in pleuro-
pneumonia-like organism (PPLO) media (BD Biosciences,
Sparks, MD) supplemented with 10 μg/ml nicotinamide
dinucleotide, 260 μg/ml L-cysteine hydrochloride, 1 mg/ml
dextrose, 10 μg/ml L-cysteine dihydrochloride, 0.6 mM
glutamine, and 0.1% Tween 80 at 37°C with continuous
shaking [32]. For whole-cell lysate preparations, A.
pleuropneumoniae was cultured to mid-log phase and
collected by centrifugation at 3,000 × g for 10 min. The
cell pellet was washed with phosphate buffered saline
(PBS, pH 7.4), lysed with lysis buffer (20 mM Tris–HCl
(pH 8.0), 0.15 M NaCl, 0.1 M EDTA, 1% SDS) and
stored at −70°C until use.
Proteins secreted by A. pleuropneumoniae into the
culture media were precipitated by the addition of 0.02%
deoxycholic acid (v/v) and 15% trichloroacetic acid (v/v)
to the supernatant. Following overnight incubation at 4°C,
the precipitate was collected by centrifugation and the
pellet was washed with cold ethanol and centrifuged.
After aspiration of the supernatant, the pellet was dried
and dissolved in PBS.
M. hyopneumoniae strains were cultured to mid-log
phase (medium pH range, 6.8–7.2) in ATCC medium 1699
at 37°C with continuous shaking [33]. Cell membranes were
isolated by osmotic lysis and sonication. Briefly, the cell pel-
let was washed with PBS, resuspended in deionized water,
and incubated at 37°C for 30 min. The suspensions were
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with a 2-s cooling period between each burst) and then
centrifuged at 10,000 × g for 20 min at 4°C. The super-
natant was centrifuged at 100,000 × g for 1 h at 4°C to
collect the cell membranes [34]. The cell membrane pellet
was dissolved in resuspension buffer (10 mM potassium
phosphate, 50 mM NaCl, 20% glycerol (v/v)) and stored
at −70°C until use.
E. coli DH5α and BL21 (DE3) strains (Stratagene, La
Jolla, CA) were used for plasmid DNA amplification and
production of recombinant proteins, respectively, and
were grown in Luria-Bertani (LB) media at 37°C with
continuous shaking.
Recombinant plasmids
To prepare the pET-ApxN plasmid vector, a fragment of
the apxIIIA gene was amplified from A. pleuropneumoniae
genomic DNA by polymerase chain reaction (PCR) using
ApxN-F and ApxN-R primers (Table 1). The PCR product
was cloned into a pGEM-T Easy vector (Promega, Madison,
WI). The TA-cloned vector was then digested with BamHI
and XhoI and the insert was ligated into linearized pET28a
(+) (Novagen, Cambridge, UK) carrying an N-terminal
histidine tag to obtain pET-ApxN.
The pET-P97C vector was constructed to express a re-
gion of the C-terminal portion of P97 (GenBank accession
number U50901). First, a DNA fragment was synthesized,
in which the nucleotide sequence of P97 was modified to
produce codons preferred by E. coli without changing the
amino acid sequence [35], and the 5’-TGA-3’ codon was
replaced with 5’-TGG-3’ (Figure 1). 5’-TGA-3’ is read
as tryptophan in Mycoplasma, but results in prematureTable 1 Oligonucleotide primers used for PCR
Primer Sequence (5' to 3') A
ApxN-F GGGGATCCGGCTACGATGTAACTAAAAATGGT
BamHI restriction sequence italicized
ApxN-R GGCTCGAGTTATTGTAAGAACTGATCCAGTTGCGG
XhoI restriction sequence italicized
P97C-F CGGGATCCAAACTGGATGACAACCTCCAA
BamHI restriction sequence italicized
P97C-R GGCTCGAGTTAAGGATCTCCGGATTTGCTGTCGTC
XhoI restriction sequence italicized
Ap97-F GGCCATATGCAAGTTAAAAAAGGCTACGATGTAAC
NdeI restriction sequence italicized
Ap97-R GGCGGATCCATGTTTTTGTTAGAACTGATCCAGTTG




Mhyop102-R AGCTGTTCAAATGCTTGTCCtermination of translation in other eubacteria, such as E.
coli [36]. The fragment was used to amplify a 954 bp-long
product encompassing the R1 and R2 regions of P97 by
PCR with P97C-F and P97C-R primers (Table 1) [37].
The product was cloned into a pGEM-T Easy vector.
The TA-cloned vector was restricted with BamHI and
XhoI, and the insert was ligated into linearized pET28a
(+) to form pET-P97C.
The pET-Ap97 vector was used to express chimeric
protein Ap97, which comprises ApxN and P97C at the N-
and C-terminus, respectively. A fragment of the apxIIIA
gene was amplified from A. pleuropneumoniae genomic
DNA by PCR using primers Ap97-F and Ap97-R (Table 1)
and cloned into a pGEM-T Easy vector. The Gly-Ser pep-
tide linker within the chimeric protein was encoded by
the sequence 5’-GGATCC-3’ within the Ap97-R primer,
or by a BamHI site. The TA-cloned vector was digested
with NdeI and BamHI and the insert was ligated into
linearized pET-P97C to yield pET-Ap97. The 5’-TAG-3’
nucleotide sequence for a Leu residue was replaced with
5’-CAG-3’ in both Ap97-R and ApxN-R primers (further
discussed in the Discussion section).
Expression and purification of recombinant proteins
Each recombinant vector was transformed into E. coli
BL21 (DE3) using a heat shock protocol. Selected colonies
were cultured at 37°C in LB media supplemented with
100 μg/ml kanamycin. Overnight cultures (diluted 1:100)
were grown until mid-log phase as indicated by an A600
between 0.5 and 0.7, at which point protein expression
was induced for 4 h by the addition of isopropyl-β-D-




AY357726 capsular polysaccharide biosynthesis 500
AF012905 P102 137
Figure 1 The optimized nucleotide sequence used to express P97C in E. coli. The R1 and R2 repeat regions of P97 adhesin are depicted by
green backgrounds. A guanine nucleotide, shown in red font, replaces an adenine nucleotide to prevent premature termination of translation
(TGA to TGG). The underlined and italicized sequences represent P97C-F and P97C-R primer binding sites, respectively.
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E. coli inclusion bodies. The cells were washed twice
with ice-cold PBS (pH 7.4) and then lysed for 30 min in
Buffer A (100 mM sodium phosphate, 10 mM Tris–HCl,
100 μg/ml lysozyme and 5 mM phenylmethanesulfonyl-
fluoride (PMSF), pH 8.0). The lysate was centrifuged at
10,000 × g for 20 min, and the resulting pellet was resus-
pended by incubation for 1 h at room temperature in
Buffer B (8 M urea, 10 mM Tris–HCl, 100 mM sodium
phosphate and 5 mM PMSF; pH 8.0). The solubilized
extracts were then loaded onto a Ni-nitrilotriacetic acid
(NTA) column (Qiagen, Chatsworth, CA). The column
was washed with Buffer C (8 M urea, 10 mM Tris–HCl,
100 mM sodium phosphate and 5 mM PMSF; pH 6.3)
and eluted with Buffers D and E (8 M urea, 10 mM
Tris–HCl, 100 mM sodium phosphate and 5 mM PMSF;
pH 5.9 and 4.5, respectively) as per the manufacturer’s
protocol.
To purify ApxN, the cells were washed with ice-cold
PBS, lysed in Buffer F (50 mM sodium phosphate,
300 mM sodium chloride, 10 mM imidazole, 1 mg/ml
lysozyme and 5 mM PMSF; pH 8.0) on ice for 30 min and
sonicated on ice using six 10-s bursts at 200–300 W with
a 10-s cooling period between each burst. The cell debris
was pelleted by centrifugation at 10,000 × g for 20 min,
and the resulting supernatant was applied to a Ni-NTA
column. The column was washed twice with Buffer G
(50 mM sodium phosphate, 300 mM sodium chloride,
20 mM imidazole, and 5 mM PMSF; pH 8.0). Proteins
bound to the Ni-NTA column were eluted with Buffer H(50 mM sodium phosphate, 300 mM sodium chloride,
250 mM imidazole, and 5 mM PMSF; pH 8.0) as per the
manufacturer’s protocol.
Purified proteins were dialyzed for 36 h at 4°C with
urea or an imidazole solution diluted serially with PBS
containing 150 mM sodium chloride and 5% glycerol.
Protein concentrations were determined using a bicinch-
oninic protein assay kit (Pierce, Rockford, IL).
Mice
All procedures for handling the mice used in this study
were reviewed and approved by the Institute of Laboratory
Animal Resources of Seoul National University and per-
formed in an ethical and humane manner under veterinary
supervision. Female Balb/c mice aged 6 to 8 weeks (SLC
Japan, Shizuoka, Japan) were divided into groups of five
animals and housed in laboratory animal facilities at the
College of Veterinary Medicine, Seoul National University.
The mice were kept in cages with access to water and food
ad libitum for 2 weeks before the first immunization. The
mice were anaesthetized with a mixture of 25 mg/kg Zoletil
(Virbac, Carros, France) and 10 mg/kg Rompun (Bayer,
Seoul, South Korea) and then immunized by subcutaneous
administration of 25 μg of immunogen (Ap97, ApxN, or
P97C) on Days 0, 14, 28, and 42. PBS-immunized mice
were included as negative controls. Immunogens or PBS
were administered in complete Freund’s adjuvant on Day
0 and in incomplete Freund’s adjuvant on Days 14, 28,
and 42. Freund’s adjuvants are potent oil-based adjuvants
that are commonly used in animal research [38].
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under anesthesia before immunization on Days 0, 14, 28,
and 42. The mice were sacrificed by cardiac puncture
3 weeks after the final immunization (Day 63), and splen-
ectomies were performed to enable the primary culture of
splenocytes.
Splenocytes and cytokine analysis
The spleens of mice immunized with Ap97, ApxN, and
P97C vaccines were aseptically removed, and single cell
suspensions were prepared by passing the organ through
a 200-μm nylon mesh sieve. Splenocytes were resuspended
in ACK buffer (0.15 M ammonium chloride, 10 mM potas-
sium bicarbonate, and 0.1 mM EDTA, pH 7.4), washed
twice with RPMI 1640 media, and cultured in RPMI 1640
media supplemented with 10% fetal bovine serum, 1 mM
sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin and 50 μM β-mercaptoethanol at
37°C under 5% CO2 in a humidified atmosphere. For ana-
lysis of cytokine production, splenocytes (4 × 106 cells/ml)
were re-stimulated for 72 h with 1.25 μg/ml of Ap97,
ApxN, or P97C dissolved in PBS. At the end of re-
stimulation, cell culture supernatants were harvested and
analyzed for IFN-γ and IL-4 using a bead-based multiplex
assay kit (Procarta cytokine assay, Panomics, Fremont,
CA), as per the manufacturer’s protocol.
Enzyme-linked immunosorbent assay (ELISA)
The immuno-reactivity of the mouse serum samples
against ApxN and P97C was measured using an indirect
ELISA. In brief, the wells of a 96-well plate were coated
with 0.5 μg of ApxN or P97C in 50 μl of carbonate buffer
(pH 9.6) overnight at 4°C. The wells were washed three
times with PBS containing 0.05% Tween 20 (PBS-T),
blocked with 5% skim milk for 2 h at 37°C, washed with
PBS-T, and then incubated with serially diluted serum
samples for 2 h at 37°C. The wells were washed and incu-
bated with peroxidase-conjugated anti-mouse IgG, IgG1,
or IgG2a (diluted 1:1,000 in PBS-T) for 1 h at 37°C. After
washing, the color was developed with o-phenylenediamine
(Amresco, Solon, OH) and 3 M HCl was used to stop
the reaction. The absorbance was measured at 450 nm
in a micro-plate spectrophotometer (Molecular Devices,
Sunnyvale, CA). The cut-off values for the assay were
calculated as the mean specific optical density (OD) plus
three standard deviations (SDs) using serum samples of
non-immunized mice (Day 0) assayed at a 1:100 dilution.
Titers were established as the reciprocal of the last serum
dilution yielding an OD higher than the cut-off.
Gel electrophoresis and western blot analysis
Protein samples were separated by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE; 8–10%
acrylamide) using a minigel apparatus (Bio-Rad, Hercules,CA) and stained with Coomassie blue. For western blot
analysis, the proteins in the SDS-PAGE gels were trans-
ferred to a Protran nitrocellulose membrane (Whatman,
Dassel, Germany) in a blotting apparatus (Bio-Rad). The
blots were blocked by incubation with 5% skim milk for
1 h and then incubated with antisera from mice or pigs
(diluted 1:500) overnight at 4°C. The blots were then incu-
bated with peroxidase-conjugated anti-mouse IgG or anti-
pig IgG (MP Biomedicals, Solon, OH) secondary antibodies
(diluted 1:5,000) for 1 h and developed with chemilumines-
cence reagents (Ab Frontier, Seoul, Korea).
Pigs
Ten 3-week-old male pigs weighing 4–6 kg were obtained
from a pathogen-free farm. Pigs were randomly divided
into two groups, housed in pens with slatted floors and
rubber mats in separate rooms, and provided with water
and food ad libitum. Pigs were shown to be free of patho-
gens by PCR analysis of nasal swabs. A 500-bp fragment
of the gene encoding a capsular polysaccharide from A.
pleuropneumoniae serotype 2 was amplified using the
AppCPS-F and AppCPS-R primers (Table 1), and a
137-bp fragment of the P102 gene from M. hyopneumoniae
was amplified using the Mhyop102-F and Mhyop102-R
primers.
After a week of acclimatization, both groups of pigs
was immunized intramuscularly with either 700 μg of
Ap97 adsorbed onto aluminum hydroxide, a standard
adjuvant in clinical veterinary vaccines [39], or 2 ml
PBS containing aluminum hydroxide as the negative
control (Day 0). A booster was inoculated on Day 14 in a
similar manner. Blood samples for immuno-serological
analysis were drawn by puncture of the vena cava cranialis
on Day 24 after the first immunization, and serum was
obtained by centrifugation for 15 min at 1,500 × g. In chal-
lenge treatments performed following blood collection, pigs
were inoculated with 7 ml culture media containing 2 × 108
colony-forming units of A. pleuropneumoniae and 1.5 × 108
color-changing units of M. hyopneumoniae by intranasal
and intratracheal administration, respectively. Clinical signs
such as rectal temperature, coughing, dyspenia, tachypnea,
depression, and nasal discharge were monitored and
recorded 2 weeks after challenge (Day 38). Pigs were
euthanized using electric current and complete necrosco-
pies were performed 21 days after challenge (Day 45). The
macroscopic lung lesion score was determined as described
previously [15,40].
Statistics
Statistical analyses were performed using SPSS 15.0 (SPSS,
Chicago, IL). Data were expressed as the mean ± SD. The
unpaired Student’s t-test was used to compare antibody
titers and macroscopic lung lesion scores. The paired
Student’s t-test was used to evaluate differences in cytokine
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when P was < 0.05.
Results
Production of recombinant proteins
SDS-PAGE analysis of proteins purified after expression
in E. coli using pET-ApxN, pET-P97C, and pET-Ap97 vec-
tors revealed prominent bands at approximately 15 kDa,
45 kDa, and 60 kDa, respectively (Figure 2A). These values
corresponded to the expected molecular weights of ApxN,
P97C, and Ap97 (a chimeric protein comprising ApxN and
P97C). These findings demonstrate that the recombinant
proteins were expressed as expected.
Immunogenicity of recombinant proteins in mice
Antiserum generated in mice immunized with the Ap97
vaccine was used to test the ability of the chimeric protein
to induce the production of antibodies specific for each of
its component subunits, ApxN and P97C, as well as to the
whole chimeric protein (Figure 2B). Antiserum against the
Ap97 vaccine reacted well with ApxN, P97C, and Ap97,
demonstrating that immunization with Ap97 induces theFigure 2 Expression and purification of ApxN, P97C, and Ap97 recom
ApxN, P97C, and Ap97 purified from E. coli BL21 using His-tag affinity chrom
Ap97 (lane 3) were approximately 15, 45, and 60 kDa, respectively, which w
analysis of ApxN, P97C, and Ap97 using antisera from mice immunized wit
obtained 3 weeks after the last immunization (Day 63).production of antibodies that bind to all three recom-
binant proteins. Thus, Ap97 retained the antigenic char-
acteristics of its two individual components. Antisera
from mice immunized with the ApxN and P97C vaccines
reacted with Ap97, and with ApxN and P97C, respect-
ively; however, antisera from mice immunized with ApxN
did not cross react with P97C and vice versa (Figure 2C
and D).
Immunization with the Ap97 and ApxN vaccines in-
duced vigorous IgG responses to ApxN in mice. The
IgG log titers reached 3.22 and 3.22 on Day 14 after
the first immunization, and 5.87 and 5.82 at 3 weeks
after the last immunization (Day 63) with Ap97 and
ApxN, respectively, which were significantly higher
than those recorded for antisera obtained from mice
given PBS (Figure 3A; P < 0.01). Immunization with the
Ap97 and P97C vaccines also increased the levels of
anti-P97C IgG antibodies in the mice, with log titers reach-
ing 5.55 and 5.23 at 3 weeks after the last immunization
(Day 63), respectively; these values are also higher than
those for the antisera obtained from mice given PBS
(Figure 3B; P < 0.01).binant proteins. A. Coomassie blue-stained SDS-PAGE gel showing
atography. The molecular masses of ApxN (lane 1), P97C (lane 2), and
ere equivalent to the expected values. B, C, and D. Western blot
h Ap97 (B), ApxN (C), or P97C (D) vaccines. The mouse antisera were
Figure 3 Serum titers of total IgG, IgG1, and IgG2a isotype antibodies against ApxN and P97C in mice immunized with ApxN, P97C,
and Ap97 vaccines. Blood samples were obtained at 0, 14, 28, 42, and 63 Days after the first immunization. A. Total IgG titers against ApxN.
B. Total IgG titers against P97C. C. IgG isotype titers against ApxN. D. IgG isotype titers against P97C. IgG1 and IgG2a titers were evaluated at
3 weeks after the last immunization (Day 63). The numbers above the columns indicate the mean IgG2a/IgG1 ratios (C and D). Data represent
the mean ± SD (n = 5). *P < 0.05 and **P < 0.01, significantly different from the corresponding anti-PBS serum controls (unpaired t-test).
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ApxN and P97C were measured in sera collected 3 weeks
after the last immunization (Day 63; Figure 3C and 3D).
The levels of both isotypes against ApxN and P97C were
higher than those in the corresponding PBS-treated
controls (P < 0.01 or P < 0.05), indicating mixed Th1-Th2
responses. However, the mean ratios of IgG2a/IgG1 against
ApxN were 7.12 and 9.53 in antisera from mice given
the Ap97 and ApxN vaccines, respectively, indicating
the predominance of IgG2a production over IgG1 and,
thus, a Th1-biased response to ApxN. By contrast, the
IgG2a/IgG1 ratios to P97C were 0.78 and 1.68 in the
antisera from mice given the Ap97 and P97C vaccines,
respectively. This demonstrates that Ap97 and P97C
induced relatively balanced IgG2a and IgG1 responses
to P97C.
Cytokine secretion induced by recombinant proteins
Re-stimulated splenic mononuclear cells (splenocytes)
from mice immunized with Ap97, ApxN, and P97C
vaccines were assayed for the production of the IFN-γ
and IL-4 (Figure 4). The concentrations of IFN-γ, a
Th1 cytokine, in the culture medium of splenocytes re-
stimulated in vitro with Ap97, ApxN, and P97C were
123.02 ± 8.23 pg/ml, 42.89 ± 15.81 pg/ml, and 61.51 ±
25.36 pg/ml, respectively. Those levels were 80.9, 29.4, and
50.8 times higher, respectively, than those re-stimulated
with PBS (control) (Figure 4A; P < 0.01 or P < 0.05).
The concentrations of IL-4, a Th2 cytokine, produced
by splenocytes re-stimulated in vitro with Ap97, ApxN,
and P97C were 18.21 ± 5.08 pg/ml, 5.36 ± 2.83 pg/ml,and 9.77 ± 2.04 pg/ml, respectively. Those levels were 43.4,
7.66 and 16.3 times higher, respectively, than those in the
PBS controls (Figure 4B; P < 0.01 or P < 0.05). Stimulation
with concanavalin A, a potent T cell stimulator, also in-
duced splenocytes (including the controls) to produce
these two cytokines (data not shown). These findings
indicate that all three recombinant proteins triggered
the production of both IFN-γ and IL-4 by splenocytes,
suggesting the induction of mixed Th1-Th2 immune
responses.
Reaction of ApxIII and P97 with mouse antisera to the
recombinant proteins
Western blots were performed to examine the reaction
of native ApxIII with mouse antisera raised against the
Ap97 and ApxN vaccines (Figure 5). A protein sample
precipitated from the culture medium of A. pleuropneu-
moniae was used for the analysis (see Methods). Anti-
sera generated in mice immunized with the ApxN and
Ap97 vaccines reacted with a precipitated protein that
was approximately 120 kDa in size, which corresponds
to the molecular weight of ApxIII [41], whereas no
protein signal was detected in the control media, indi-
cating that the antibodies generated in response to vaccin-
ation with Ap97 and ApxN readily bind to the ApxIII
excreted by A. pleuropneumoniae. These data suggest
that Ap97, as well as ApxN, possess the antigenic charac-
teristics of the ApxIII protein, which are recognized by the
mouse immune system.
Antisera from mice immunized with the Ap97 and P97C
vaccines were also assayed for reaction with P97, found in
Figure 4 Cytokine profiles of splenocytes obtained from immunized mice. Mice were primed with Ap97, ApxN, or P97C vaccines. Splenocytes
were isolated from each mouse and then re-stimulated with Ap97, ApxN, or P97C dissolved in PBS. At the end of re-stimulation, cell culture supernatants
were analyzed for IFN-γ (A) and IL-4 (B). Data represent the mean ± SD (n = 4). *P < 0.05 and **P < 0.01, significantly different from the corresponding
PBS-treated controls (paired t-test).
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The antisera detected bands of approximately 97 KDa, the
predicted size of P97. These data suggest that both Ap97
and P97C retain the antigenic characteristics of native P97.
In addition, serum from a pig artificially infected with M.
hyopneumoniae reacted with the 97 kDa protein. All three
antisera also reacted with two other proteins (30 and
60 kDa), and the pig antiserum detected an additional
band at 70 kDa. These protein bands, including P97, were
not recognized by the control serum.Immunogenicity of Ap97 in pigs
We also assessed the reactivity of Ap97 vaccine-treated
pig serum against native P97 and ApxIII (Figure 7). Anti-
serum to the Ap97 vaccine recognized protein bands of
the expected molecular masses; 97 kDa in the cell mem-
brane fraction of M. hyopneumoniae and 120 kDa in the
culture media and cell lysate of A. pleuropneumoniae.
The data are representative of six experiments, in which
independent antiserum samples were used. In addition,Figure 5 Recognition of A. pleuropneumoniae ApxIII by antisera from
Western blot analyses were performed with ApxN-vaccinated (A) and Ap97
pleuropneumoniae 1536 culture media (Lane 1) and control media (Lane 2)the serum from pigs treated with PBS did not react with
P97 or ApxIII. These data suggest that antibodies induced
in pigs vaccinated with Ap97 efficiently react with P97
and ApxIII, and that both domains of the Ap97 protein
are immunogenic in pigs.Protective efficacy of Ap97 in pigs
Since pigs immunized with Ap97 produced antibodies
against P97 and ApxIII (Figure 7), the pigs were directly
subjected to challenge with M. hyopneumoniae and A.
pleuropneumoniae. The PBS vaccine-treated control pigs
that were challenged with A. pleuropneumoniae and M.
hyopneumoniae showed an increased body temperature
and developed clinical symptoms, including coughing,
dyspnea, depression, and nasal discharge (Table 2). Post-
mortem examination revealed that all the PBS-immunized
pigs had numerous gross pathological changes linked to
A. pleuropneumoniae and M. hyopneumoniae (Figure 8).
The lungs of the PBS-vaccinated pigs developed well-
demarcated dark red areas of cranioventral consolidation,mice immunized with the Ap97 or ApxN recombinant proteins.
-vaccinated (B) mouse sera for proteins precipitated from A.
. Arrows indicate the target band size.
Figure 6 Recognition of M. hyopneumoniae P97. The cell membrane
fraction from M. hyopneumoniae was subjected to western blot analysis
with Ap97-vaccinated mouse serum (Lane 1), P97C-vaccinated mouse
serum (Lane 2), the serum of a pig experimentally infected with M.
hyopneumoniae (Lane 3), and PBS-vaccinated control mouse serum
(Lane 4). An arrow indicates the target band size.
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and also developed multifocal hemorrhages and fibrinous
pleurisy that are classic presentation of A. pleuropneumo-
niae disease [1,3,14,15]. In contrast, no remarkable clinical
signs or lung lesions were observed in the Ap97-vaccinated
group (with the exception of mild coughing in one pig).
Discussion
There is a high demand for multi-disease and multivalent
vaccines in the animal health industry. However, combining
vaccine antigens causes a variety of problems, including
interference between the various components, antigenic
competition, and carrier-specific epitope suppression
[42-44]. Thus, combined formulations must be shown
to be both safe and effective before licensure. Numerous
examples of immunological interference have been ob-
served in laboratory tests and clinical trials [45]. One
relevant example involves a study of immunity against
A. pleuropneumoniae in swine, in which the protective
efficacy of an ApxI/ApxII vaccine was lost when it wasFigure 7 Recognition of M. hyopneumoniae P97 and A. pleuropneumoni
vaccine. A. Western blot analysis of the cell membrane fraction of M. hyopne
media (Lane 2) and cell lysate (Lane 3) of A. pleuropneumoniae was performed
samples described in panel A was performed with PBS-vaccinated pig serumsupplemented with PalA, an outer membrane protein
derived from the pathogen [11].
The first 160 residues of the ApxIII N-terminus are
involved in its cytotoxicity and pro-apoptotic activity,
and convalescent serum collected from a pig infected with
A. pleuropneumoniae reacted with the N-terminus [46].
Based upon these findings, the region encompassing resi-
dues 21–131 of ApxIII was used to construct Ap97. In
preliminary studies, the first 20 residues of ApxIII were
also included, but the expression efficiency was very low
(data not shown). This could be due to the inclusion of
two under-represented Arg codons (AGG and AGA) at
residues 14 and 20, respectively. In E. coli, AUA (Ile),
CUA (Leu), and AGA, AGG, or CGA (Arg), represent less
than 8% of their corresponding population of codons [47].
Another rarely-observed codon, CUA, at residue 124 of
ApxIII was replaced with CUG using an Ap97-R primer
that contains a single base substitution (Table 1). This was
also the case for the expression of ApxN.
The expression of recombinant proteins, especially
chimeric proteins, can result in aberrant tertiary folding
of the expressed protein; correct folding is critical for
maintaining the antigenic characteristics. It was not estab-
lished whether or not both components of Ap97 protein
possessed the correct tertiary structure. However, Ap97
retained the antigenic properties of its two component
proteins, ApxN and P97C (Figure 2), and antisera from
mice and pigs immunized with Ap97 readily reacted with
native ApxIII and P97 from A. pleuropneumoniae and M.
hyopneumoniae, respectively (Figures 5, 6, 7). In addition,
immunization with the Ap97 vaccine induced humoral
and cellular immune responses in mice (Figures 3 and 4),
and pigs immunized with the Ap97 vaccine were pro-
tected against challenge by A. pleuropneumoniae and M.
hyopneumoniae (Table 2). These findings suggest that
Ap97 contains antigenic epitopes similar to those of native
ApxIII and P97.
IL-4 activates B cells and induces class switching to
the IgG1 isotype (a Th2 type immune response), while
IFN-γ induces IgG2a responses (Th1 type) [48,49]. A Th1
antibody response is involved in protection from infection,
while a Th2 response is helpful for clearing the infection.
Thus, an ideal vaccine should enhance Th1 responsesae ApxIII by serum isolated from pigs immunized with the Ap97
umoniae (Lane 1) as well as TCA-precipitated proteins from the culture
with Ap97-vaccinated pig serum. B. Western blot analysis of the protein
. Arrows indicate target band sizes.
Table 2 Protection of pigs with Ap97 vaccine against A. pleuropneumoniae and M. hyopneumoniae infection
Immunogen Challenge Body
temperaturea
# of pigs with clinical signs / # of pigs challenged Lung lesion




Ap97 A. pleuropneumoniae and
M. hyopneumoniae
-,-,-,-,-,- 1/6 0/6 0/6 0/6 2.00 ± 0.71*
PBS A. pleuropneumoniae and
M. hyopneumoniae
+,+,++,++,++,++ 6/6 5/6 5/6 6/6 62.30 ± 4.38
aMaximum measured rectal temperature. –, ≤ 39.5°C; +, 39.5 to 42°C; ++, ≥ 42°C.
bTotal area (0–100%) of the lung affected by any type of pneumonia lesion [51]. Data are presented as the mean ± SD (n = 6). *P < 0.01, significantly different from
the corresponding PBS-treated group (unpaired t-test).
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induced secretion of both Th1 and Th2 cytokines by
splenocytes (Figure 4). Along with an increase in cytokine
levels, the levels of both the IgG1 and IgG2a isotypes
specific for ApxN and P97C were also increased in the
sera of Ap97-immunized mice (Figure 3). These indi-
cate that Ap97 induced a mixed Th1-Th2 response.
P97C induced balanced IgG1 and IgG2 responses in
mice (Figure 3). By contrast, ApxN induced IgG2a
more than IgG1, indicating a Th1-biased response to
ApxN. This difference in the responses elicited by the
two components of Ap97 is interesting; however, the
underlying mechanism is unclear. Previous studies indi-
cate that the pattern of IgG isotypes induced by protein
vaccines depends on the adjuvants and protein antigens
used [50-52].
Of the three recombinant proteins, Ap97 induced the
greatest concentrations of IFN-γ and IL-4 in the culture
media of re-stimulated splenocytes (Figure 4). Notably,
the concentration of IFN-γ in the media from Ap97-
stimulated cells was a bit higher than the sum of the
cytokine concentrations in the media from ApxN and
P97C-stimulated cells. This was also the case for IL-4.
These suggest that both components of Ap97 do not
interfere each other on cytokine induction.
The membrane fraction of M. hyopneumoniae con-
tained not only P97 but different-sized proteins, whichFigure 8 Ventral surfaces of lungs from Ap97 (A)- and PBS (B)-vaccina
M. hyopneumoniae.were recognized by serum from a pig artificially in-
fected with M. hyopneumoniae as well as antisera from
mice immunized with the Ap97 and P97C vaccines
(Figure 6). Based on previous studies that identified
different-sized cleavage products of P97, the non-
97 kDa proteins may represent cleavage products of
P97 [22,27,53].Conclusions
The chimeric protein, Ap97, was both immunogenic and
effective as a vaccine under the conditions of these ex-
periments. To the best of our knowledge, this is the
first study to demonstrate the prevention of infection
by A. pleuropneumoniae and M. hyopneumoniae using
a multi-disease subunit vaccine. The only previous re-
port related to multi-disease vaccination against these
two pathogens was based on immunization with a live
attenuated strain of A. pleuropneumoniae, which was
engineered to express M. hyopneumoniae P36 [54].
While the results of this study are limited to two proteins
derived from these pathogens, it will be interesting to
evaluate the potential of other proteins derived from these
microorganisms, especially ApxI, ApxII, and ApxIV toxins
from various A. pleuropneumoniae serotypes, to con-
tribute to the development of safer and more effective
multi-disease vaccines.ted pigs at day 21 post-challenge with A. pleuropneumoniae and
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